Dr. Reddy's Laboratories Limited
RDYHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeReddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. At a $11.38B market cap, Dr. Reddy's Laboratories Limited ranks as a large-cap company within healthcare. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.
Market Cap
$11.38B
Beta
0.29
P/E (TTM)
25.72
P/E (Fwd)
20.31
EPS (TTM)
$0.53
EPS (Fwd)
$0.67
ROE
11.8%
ROA
5.8%
Cash
$87.81B
Total Debt
$77.34B
Free CF
$1.74B
52W Change
-7.5%
Annual Financials
Cash vs Debt
With $87.81B in cash and $77.34B in debt, RDY maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $1.74B supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 11.8% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.8% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $245.88B (2023) to $335.93B (2026), reflecting a 37% increase over the period.
The relatively low beta of 0.29 suggests RDY is a less volatile holding compared to the broader index. No single metric tells the full story. Reviewing RDY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.